PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.94

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 78.92B
ARGX argenx NV ADR

N/A

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 30.22B
MRNA Moderna Inc

N/A

USD 18.29B
UTHR United Therapeutics Corporatio..

N/A

USD 15.91B
RPRX Royalty Pharma Plc

N/A

USD 15.05B
SMMT Summit Therapeutics PLC

N/A

USD 13.43B
INCY Incyte Corporation

N/A

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 12.74B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.68% 60% D- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.68% 60% D- 68% D+
Trailing 12 Months  
Capital Gain -63.20% 26% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.20% 26% F 12% F
Trailing 5 Years  
Capital Gain -85.47% 40% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.47% 40% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -23.93% 17% F 9% A-
Dividend Return -23.93% 17% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.10% 92% A 68% D+
Risk Adjusted Return -91.69% 8% B- 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.